Wealthspire Advisors (New York)’s Ocular Therapeutix OCUL Stock Holding History

Wealthspire Advisors (New York)’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	+162,960	New	+$1.48M	0.01%	464

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wealthspire Advisors (New York)'s OCUL Position: Q2 2026 in Review

Wealthspire Advisors (New York) opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 162,960 shares worth $1.6M. The stake represents 0.01% of the portfolio and ranks #464 among its holdings.

261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Wealthspire Advisors (New York) held 162,960 shares of Ocular Therapeutix worth $1.6M as of Q2 2026.
Ocular Therapeutix was a new Wealthspire Advisors (New York) position in Q2 2026.
Ocular Therapeutix made up 0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #464 holding.
261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.